+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Schizophrenia Epidemiology Forecast 2025-2034

  • PDF Icon

    Report

  • 150 Pages
  • June 2025
  • Region: Global
  • Expert Market Research
  • ID: 6102506
Schizophrenia causes considerable disability and may impact all areas of life. Around 1 in 300 people or 24 million individuals worldwide are affected by schizophrenia. The onset of this mental disorder is reported to be typically during late adolescence and the twenties and tends to occur earlier among men than in women.

Schizophrenia Epidemiology Forecast Report Coverage

The “Schizophrenia Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of schizophrenia. It projects the future incidence and prevalence rates of schizophrenia across various populations. The study covers age, gender, and type as major determinants of the schizophrenia-affected population. The report highlights patterns in the prevalence of schizophrenia over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of schizophrenia in the 8 major markets.

Regions Covered

  • The United States
  • Germany
  • France
  • Italy
  • Spain
  • The United Kingdom
  • Japan
  • India

Schizophrenia Disease Overview

Schizophrenia is a chronic brain disorder that is characterized primarily by disconnection from reality, including delusions and hallucinations, disorganized thinking and behavior, and decreased participation in daily activities. It is suggested that a combination of genetics, altered brain structure and chemistry, and environmental factors are involved in the development of this mental disorder. Diagnosis of schizophrenia is based on a detailed psychiatric evaluation, history, and symptom analysis. Brain imaging, such as MRI and CT scans, may show structural abnormalities in the affected patient.

Schizophrenia: Treatment Overview

For the treatment of schizophrenia, a combination of medications, psychotherapy, and support services are used to manage symptoms and improve quality of life. First-generation (haloperidol) and second-generation (olanzapine, risperidone) antipsychotic medications are usually prescribed to control symptoms. Psychotherapy, including cognitive behavioral therapy (CBT) and family therapy, is also a popular treatment option for schizophrenia patients to cope with delusions, and hallucinations, and improve social functioning.

Epidemiology

The schizophrenia epidemiology section offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for schizophrenia by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for schizophrenia and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.
  • There are about 24 million people who are suffering from schizophrenia, with the rate estimated to be 1 in 222 people or 0.45% among adults.
  • Schizophrenia is usually diagnosed in the late teens to early thirties, with males typically experiencing symptoms earlier (late teens to early twenties) than females (early twenties to early thirties).
  • In 2020, schizophrenia was estimated to affect 1.1% of the population, or about 2.8 million adults aged 18 and older in the United States, as per the Treatment Advocacy Center, a US-based non-profit organization.
  • Various studies report that schizophrenia is more common in men than women, with a ratio of around 1.4:1 and onset occurring 3.2 to 4.1 years earlier in males. However, some studies show no lifetime prevalence difference between the genders.

Country-wise Schizophrenia Epidemiology

The schizophrenia epidemiology data and findings for the United States, EU-4 (Germany, Spain, Italy, France), the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of schizophrenia varies between countries owing to differences in factors such as genetic predispositions, diagnostic practices, levels of awareness, access to healthcare, cultural perceptions of mental health, and lifestyle factors, among others. It is estimated that around 1% of Americans suffer from schizophrenia, according to the National Institute of Mental Health Disorders.

Scope of the Report

  • The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of schizophrenia based on several factors.
  • Schizophrenia Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
  • The report helps to identify the patient population and the unmet needs of schizophrenia are highlighted along with an assessment of the disease's risk and burden.

Key Questions Answered

  • What are the key findings of schizophrenia epidemiology in the 8 major markets?
  • What will be the total number of patients with schizophrenia across the 8 major markets during the forecast period?
  • What was the country-wise prevalence of schizophrenia in the 8 major markets in the historical period?
  • Which country will have the highest number of schizophrenia patients during the forecast period of 2025-2034?
  • Which key factors would influence the shift in the patient population of schizophrenia during the forecast period of 2025-2034?
  • What are the currently available treatments for schizophrenia?
  • What are the disease risks, signs, symptoms, and unmet needs of schizophrenia?

This product will be delivered within 3-5 business days.

Table of Contents

1 Preface
1.1 Introduction
1.2 Objectives of the Study
1.3 Research Methodology and Assumptions
2 Executive Summary
3 Schizophrenia Market Overview - 8 MM
3.1 Schizophrenia Market Historical Value (2018-2024)
3.2 Schizophrenia Market Forecast Value (2025-2034)
4 Schizophrenia Epidemiology Overview - 8 MM
4.1 Schizophrenia Epidemiology Scenario (2018-2024)
4.2 Schizophrenia Epidemiology Forecast (2025-2034)
5 Disease Overview
5.1 Signs and Symptoms
5.2 Causes
5.3 Risk Factors
5.4 Guidelines and Stages
5.5 Pathophysiology
5.6 Screening and Diagnosis
5.7 Types of Schizophrenia
6 Patient Profile
6.1 Patient Profile Overview
6.2 Patient Psychology and Emotional Impact Factors
7 Epidemiology Scenario and Forecast - 8 MM (218-2034)
7.1 Key Findings
7.2 Assumptions and Rationale
7.3 Diagnosed Prevalent Cases of Schizophrenia
7.4 Type-Specific Cases of Schizophrenia
7.5 Gender-Specific Cases of Schizophrenia
7.6 Age-Specific Cases of Schizophrenia
8 Epidemiology Scenario and Forecast: United States (218-2034)
8.1 Assumptions and Rationale in the United States
8.2 Diagnosed Prevalent Cases of Schizophrenia in the United States
8.3 Type-Specific Cases of Schizophrenia in the United States
8.4 Gender-Specific Cases of Schizophrenia in the United States
8.5 Age-Specific Cases of Schizophrenia in the United States
9 Epidemiology Scenario and Forecast: United Kingdom (218-2034)
9.1 Assumptions and Rationale in the United Kingdom
9.2 Diagnosed Prevalent Cases of Schizophrenia in the United Kingdom
9.3 Type-Specific Cases of Schizophrenia in the United Kingdom
9.4 Gender-Specific Cases of Schizophrenia in the United Kingdom
9.5 Age-Specific Cases of Schizophrenia in the United Kingdom
10 Epidemiology Scenario and Forecast: Germany (218-2034)
10.1 Assumptions and Rationale in Germany
10.2 Diagnosed Prevalent Cases of Schizophrenia in Germany
10.3 Type-Specific Cases of Schizophrenia in Germany
10.4 Gender-Specific Cases of Schizophrenia in Germany
10.5 Age-Specific Cases of Schizophrenia in Germany
11 Epidemiology Scenario and Forecast: France (218-2034)
11.1 Assumptions and Rationale in France
11.2 Diagnosed Prevalent Cases of Schizophrenia in France
11.3 Type-Specific Cases of Schizophrenia in France
11.4 Gender-Specific Cases of Schizophrenia in France
11.5 Age-Specific Cases of Schizophrenia in France
12 Epidemiology Scenario and Forecast: Italy (218-2034)
12.1 Assumptions and Rationale in Italy
12.2 Diagnosed Prevalent Cases of Schizophrenia in Italy
12.3 Type-Specific Cases of Schizophrenia in Italy
12.4 Gender-Specific Cases of Schizophrenia in Italy
12.5 Age-Specific Cases of Schizophrenia in Italy
13 Epidemiology Scenario and Forecast: Spain (218-2034)
13.1 Assumptions and Rationale in Spain
13.2 Diagnosed Prevalent Cases of Schizophrenia in Spain
13.3 Type-Specific Cases of Schizophrenia in Spain
13.4 Gender-Specific Cases of Schizophrenia in Spain
13.5 Age-Specific Cases of Schizophrenia in Spain
14 Epidemiology Scenario and Forecast: Japan (218-2034)
14.1 Assumptions and Rationale in Japan
14.2 Diagnosed Prevalent Cases of Schizophrenia in Japan
14.3 Type-Specific Cases of Schizophrenia in Japan
14.4 Gender-Specific Cases of Schizophrenia in Japan
14.5 Age-Specific Cases of Schizophrenia in Japan
15 Epidemiology Scenario and Forecast: India (218-2034)
15.1 Assumptions and Rationale in India
15.2 Diagnosed Prevalent Cases of Schizophrenia in India
15.3 Type-Specific Cases of Schizophrenia in India
15.4 Gender-Specific Cases of Schizophrenia in India
15.5 Age-Specific Cases of Schizophrenia in India
16 Patient Journey17 Treatment Challenges and Unmet Needs18 Key Opinion Leaders (KOL) Insights